GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn update from GH Research ( (GHRS) ) is now available. On January 8, 2025, GH Research PLC reported that it will present new clinical data from its GH001-TRD-201 and GH001-BD-202 trials at the 64th American College of Neuropsychopharmacology annual meeting, to be held January 12–15, 2026, in Paradise Island, Bahamas. The accepted posters cover Phase 2b results on rapid antidepressant effects of inhaled GH001 in treatment-resistant depression, detailed safety findings regarding suicidal ideation and behavior in TRD patients, and Phase 2a data in bipolar II disorder with a current major depressive episode. The TRD Phase 2b study, which included a 7‑day randomized, double-blind period followed by a six‑month open-label extension, found that GH001 was generally well tolerated, produced significant reductions in depressive symptoms and did not increase suicidal ideation or suicidal behavior over six months, with no treatment-emergent events involving suicidal intent or behavior and only one transient case of suicidal ideation. These findings, together with the broader program data being showcased at a major neuropsychopharmacology forum, underscore GH001’s potential as a rapid-acting antidepressant option for high-risk TRD and bipolar depression populations, addressing a significant unmet need for therapies that do not exacerbate suicide risk. The most recent analyst rating on (GHRS) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page. Spark’s Take on GHRS Stock According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral. The score is held back primarily by weak operating fundamentals (no revenue, widening losses, and significant cash burn), partially offset by a strong, low-debt balance sheet. Technicals are moderately supportive with price above key moving averages, while valuation remains constrained due to negative earnings and no dividend data. To see Spark’s full report on GHRS stock, click here. More about GH Research GH Research PLC is a Dublin-based biopharmaceutical company developing novel therapies for psychiatric disorders, with a focus on treatment-resistant depression (TRD) and bipolar II disorder. Its lead asset, GH001, is a synthetic, inhaled form of mebufotenin (5-MeO-DMT) being evaluated in mid-stage clinical trials for rapid antidepressant effects in patients with difficult-to-treat mood disorders. Average Trading Volume: 432,388 Technical Sentiment Signal: Buy Current Market Cap: $875.9M For an in-depth examination of GHRS stock, go to TipRanks’ Overview page.